Rivoceranib for metastatic thymus gland cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new pill, rivoceranib, for people with a rare type of thymus cancer that has spread and has grown despite prior treatment. The drug works by blocking blood supply to the tumor, which may help slow or shrink it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 or older.
- You have a thymic epithelial tumor that has spread to other parts of the body.
- Your tumor has gotten bigger or come back after at least one standard treatment.
- You are not a candidate for surgery and you need more treatment.
- You are able to be up and about (ECOG performance status 0 or 1).
- Your kidneys, liver, and bone marrow are working well enough (blood tests will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies PT-112, a new treatment, in people with thymoma or thymic carcinoma that has grown despite at least one prior platinum chemotherapy treatment. It may help shrink tumors or slow disease progression, especially when surgery is not possible.
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
This trial tests a combination of new drugs (SHR-1701, Rivoceranib, and possibly SHR-2554) for people with advanced stomach cancer whose disease has continued to grow after immunotherapy. It aims to find a better treatment option for those who have not had success with standard therapy.
This trial tests a new drug called ivonescimab for thymic carcinoma that has come back or isn't responding to other treatments. It aims to see if this drug can shrink the cancer and help you feel better.
This trial tests a combination of an immunotherapy drug (ivonescimab) plus chemotherapy as the first treatment for people with advanced or recurrent thymic cancer. The goal is to see how well this combination works and how safe it is.
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Hear when a new Thymic Epithelial Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.